This trial is active, not recruiting.

Conditions adrenocortical carcinoma, cushing's syndrome
Phase phase 0
Sponsor University of Wuerzburg
Collaborator Deutsche Krebshilfe e.V., Bonn (Germany)
Start date September 2005
End date December 2011
Trial size 70 participants
Trial identifier NCT00457587, Wue-Immuno-ACC-83/05


Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Primary Outcomes

To find reasonable antigens for a vaccination therapy in ACC
time frame: day of blood sampling
To investigate the role of tumor-induced suppression in ACC
time frame: NA, in vitro study

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - patients with histological proven adrenocortical carcinoma - healthy persons as control group - Life expectancy > 6 months Exclusion Criteria: - autoimmune diseases - severe clinical condition

Additional Information

Official title Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Principal investigator Martin Fassnacht, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by University of Wuerzburg.